Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
TFF Pharmaceuticals, Inc. (TFFP) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 8-K Quarterly results
Docs: "UNDERWRITING AGREEMENT",
"OPINION OF GREENBERG TRAURIG, LLP",
"TFF Pharmaceuticals Announces Proposed Public Offering of Common Stock FORT WORTH, Texas, August 14, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock in the underwritten public offering are to be sold by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock offered in the public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or a...",
"TFF Pharmaceuticals Prices $5 Million Public Offering of Common Stock FORT WORTH, Texas, August 15, 2023 – TFF Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that it has priced its underwritten public offering of 19,896,000 shares of its common stock at a public offering price of $0.25 per share. All of the securities in the underwritten public offering are to be sold by the Company. The Company expects the gross proceeds from this offering to be $4.97 million, before deducting the underwriting discount and other estimated offering expenses. The Company has granted the underwriter a 30-day option to purchase up to 2,984,400 add...",
"TFF PHARMACEUTICALS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Grant revenue $ 333,351 $ 28,004 $ 384,780 $ 95,439 Operating expenses: Research and development 2,681,898 5,102,090 6,700,557 10,339,514 General and administrative 2,670,363 3,678,119 5,789,579 6,891,317 Total operating expenses 5,352,261 8,780,209 12,490,136 17,230,831 Loss from operations Other income : Interest income 36,120 5,880 71,199 13,065 Change in fair value of note receivable - - Total other income , net 5,880 33,783 13,065 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average common shares outstanding, basic and diluted 36,193,085 25,373,706 36,193,085 25,372,749 5 TFF PHARMACEUTICALS, INC. CON...",
"THE COMPANY'S CORPORATE UPDATE AND PRESENTATION MATERIALS"
05/11/2023 8-K Quarterly results
Docs: "TFF Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results"
04/06/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "FIRST AMENDED AND RESTATED BYLAWS OF TFF PHARMACEUTICALS, INC."
03/08/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "TFF Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results"
02/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
01/11/2023 8-K Quarterly results
12/08/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
09/30/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/24/2022 8-K Investor presentation, Quarterly results
Docs: "TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update",
"THE COMPANY'S INVESTOR PRESENTATION MATERIALS"
12/21/2021 8-K Investor presentation
Docs: "THE COMPANY'S INVESTOR PRESENTATION MATERIALS"
11/10/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/12/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/26/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
12/04/2020 8-K Other Events
12/04/2020 8-K Other Events
11/05/2020 8-K Quarterly results
Docs: "TFF Pharmaceuticals Reports Third Quarter 2020 Financial and Business Results"
10/01/2020 8-K Quarterly results
09/29/2020 8-K Quarterly results
08/13/2020 8-K Quarterly results
08/11/2020 8-K Quarterly results
05/14/2020 8-K Quarterly results
Docs: "TFF Pharmaceuticals Reports First Quarter 2020 Financial and Business Results"
03/26/2020 8-K Quarterly results
01/31/2020 8-K Appointed a new director
12/17/2019 8-K Other Events

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy